Zobrazeno 1 - 10
of 50
pro vyhledávání: '"Esther P. Black"'
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-12 (2017)
Abstract Our previous work identified a 13-gene miRNA signature predictive of response to the epidermal growth factor receptor (EGFR) inhibitor, erlotinib, in Non-Small Cell Lung Cancer cell lines. Bioinformatic analysis of the signature showed a fun
Externí odkaz:
https://doaj.org/article/63a108947c5040c98b9e1ac1ac2632b6
Autor:
Madeline Krentz Gober, Robert M Flight, Joshua Lambert, Hunter Moseley, Arnold Stromberg, Esther P Black
Publikováno v:
Cancer Informatics, Vol 18 (2019)
KRAS-activation mutations occur in 25% to 40% of lung adenocarcinomas and are a known mechanism of epidermal growth factor receptor inhibitor (EGFRI) resistance. There are currently no targeted therapies approved specifically for the treatment of KRA
Externí odkaz:
https://doaj.org/article/a5ea0e7c18214930b453fbac1f719a46
Publikováno v:
Inorg Chem
Transition-metal-based approaches to selectively modify proteins hold promise in addressing challenges in chemical biology. Unique bioorthogonal chemistry can be achieved with preformed metal-based compounds; however, their utility in native protein
Publikováno v:
Cancer Informatics, Vol 16 (2017)
Purpose: Immune checkpoint inhibition reactivates the immune response against cancer cells in multiple tissue types and has been shown to induce durable responses. However, for patients with autoimmune disorders, their conditions can worsen with this
Externí odkaz:
https://doaj.org/article/922b028c8576452c9cf438350255a5c2
Publikováno v:
Pharmacy Education. 20:324-335
Objective: The goal of this study was to determine what students need to know about biochemistry in order to practice pharmacy. Methods: With reference to a list of learning objectives, educators interviewed students during their advanced clinical ro
Publikováno v:
PLoS ONE, Vol 16, Iss 8, p e0256416 (2021)
PLoS ONE
PLoS ONE
The identification of novel therapies, new strategies for combination of therapies, and repurposing of drugs approved for other indications are all important for continued progress in the fight against lung cancers. Antibodies that target immune chec
Autor:
Wei Zhou, Ping Yue, Taofeek K. Owonikoko, Esther P. Black, Shi-Yong Sun, Justin M. Balko, Fadlo R. Khuri, You-Take Oh
Publikováno v:
J Biol Chem
Oncogenic mutations of ras and B-raf frequently occur in many cancer types and are critical for cell transformation and tumorigenesis. Death receptor 5 (DR5) is a cell surface pro-apoptotic death receptor for tumor necrosis factor-related apoptosis-i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8aa91d68ab70b5a1987a3072c41d0e7
https://europepmc.org/articles/PMC7324490/
https://europepmc.org/articles/PMC7324490/
Publikováno v:
Thrombosis Research. 158:49-58
Statins have been shown to have a protective effect for venous thromboembolism (VTE) in the general population. This study sought to assess the association between statins and the risk for cancer-associated deep vein thrombosis (DVT) and pulmonary em
Autor:
Hunter N. B. Moseley, Robert M. Flight, Esther P. Black, Madeline Krentz Gober, Joshua Lambert, Arnold J. Stromberg
Publikováno v:
Cancer Informatics
Cancer Informatics, Vol 18 (2019)
Cancer Informatics, Vol 18 (2019)
KRAS-activation mutations occur in 25% to 40% of lung adenocarcinomas and are a known mechanism of epidermal growth factor receptor inhibitor (EGFRI) resistance. There are currently no targeted therapies approved specifically for the treatment of KRA
Publikováno v:
American journal of pharmaceutical education. 83(2)
Many external drivers may be influencing a paradigm shift in graduate education. Workforce dynamics are driving a re-examination of what is instructed in graduate programs as well as how curricula are delivered. Most graduate programs have made incre